Research & Education

Novel EGFR TKIs for Advanced EGFR Mutant Advanced NSCLC

March 13, 2018 at 7:00 P.M. CET (Central European Time)

In patients with advanced EGFR mutant NSCLC, recent data on second generation EGFR TKI dacomitinib and third-line generation EGFR TKI osirmetinib shows improved efficacy when compared to first generation drugs such as gefitinib or erlotinib.

Immunotherapy for Early and Locally-Advanced Non-Small Cell Lung Cancer

March 13, 2018 at 9:00 P.M. EDT

Immunotherapy now has become an integral part of the management of advanced NSCLC.

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Linase Inhibitors 2018

March 8, 2018 at 9:00 P.M. EST

The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) have updated and revised their 2013 evidence-based "Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors."

Mesothelioma Update

February 27, 2018 at 9:00PM EST

After attending this session attendees will be able to address the current state-of-the-art for treatment of malignant pleural mesothelioma.

Treatment Strategies for ROS1 Non-Small Cell Lung Cancer

February 6, 2018 at 7:00PM CET (Central European Time)

Recent advances in NSCLC treatment include the identification of targetable molecular subtypes beyond EGFR and ALK. ROS1 rearrangement is a distinct molecular subgroup of NSCLC patients with active therapeutic approaches.

Promising Novel Approaches to Lung Cancer

January 23, 2018 at 9:00PM EDT - Recording Available

Much has changed in the treatment landscape of non-small cell lung cancer (NSCLC) over the last few years.

Liquid Biopsy for the Management of Non-Small Cell Lung Cancer

January 16, 2018 at 4:00PM CET (Central European Time) - Recording Available

There has been a proliferation of liquid biopsy tests in the last few years. A range of tests are now available, from single mutation assays to sequencing panels of multiple genes.

Small Cell Lung Cancer: Is It Time for Biomarker-directed Therapy?

January 11, 2018 at 9:00 P.M. EST - Recording Available

For the past four decades, advances of any nature in the management of small cell lung cancer (SCLC) have been elusive, and the grim prognosis for patients diagnosed with this disease remained unchanged.

Smoking Cessation Within Tobacco Control: "Probably Not What You're Thinking"

December 20, 2017 at 7:00PM CET (Central European Time) - Recording Available

This webinar will address what is occurring in the field of smoking cessation.

Evolution of Small Cell Lung Cancer Therapy: Chemotherapy and Beyond

December 6, 2017 at 9:00 P.M. EST - Recording Available

This program will provide an update of current standards of therapy for first- and second line treatment of extensive-stage small cell lung cancer (SCLC).

Pages